Young Lee, MD
Hematology & Oncology · Charleston, SCNPI 1528036498
Payments from drug & device makers
Across 127 payments — averaging $2661.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$176K
- AstraZeneca$107K
- Pfizer$53K
- Gilead$234
- Merz North America, Inc.$232
- Johnson & Johnson$200
- plus $1K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 47 | $175,668 |
| AstraZeneca | 8 | $107,002 |
| Pfizer | 14 | $53,352 |
| Gilead | 10 | $234 |
| Merz North America, Inc. | 3 | $232 |
| Johnson & Johnson | 3 | $200 |
| Dermavant Sciences, Inc. | 2 | $167 |
| GSK | 4 | $131 |
| Incyte Corporation | 2 | $125 |
| Merck | 4 | $100 |
| Lilly USA, LLC | 3 | $90 |
| Seagen Inc. | 1 | $80 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $79 |
| Genentech USA, Inc. | 3 | $70 |
| Tersera Therapeutics LLC | 2 | $51 |
| Accord Healthcare, Inc. | 2 | $45 |
| ADC Therapeutics America, Inc. | 2 | $44 |
| Mirati Therapeutics, Inc. | 2 | $41 |
| Iovance Biotherapeutics, Inc. | 1 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Pharmaessentia USA Corporation | 1 | $33 |
| Coherus Oncology, Inc. | 1 | $30 |
| Eisai Inc. | 1 | $30 |
| Taiho Oncology, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Sobi, Inc | 1 | $26 |
| Biocon Biologics Inc | 1 | $26 |
| Corcept Therapeutics | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $20 |
How this compares
$338,057 in reported general payments places this provider in the 85th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Charleston
- Robert StuartCharleston$2.9M
- Brian LingerfeltCharleston$1.1M
- James OrcuttCharleston$1.1M
- George GeilsCharleston$930K
- John WrangleCharleston$919K
- David EllisonCharleston$767K
- George KeoghCharleston$745K
- Russell JenkinsCharleston$627K
- Irl GreenwellCharleston$376K
- Ming LimCharleston$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.